S
Sonya Li
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 2
Citations - 324
Sonya Li is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Somatic evolution in cancer. The author has an hindex of 2, co-authored 2 publications receiving 82 citations.
Papers
More filters
Journal ArticleDOI
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton,Ryan Ptashkin,Teng Gao,Lior Z. Braunstein,Sean M. Devlin,Daniel Kelly,Minal Patel,Antonin Berthon,Aijazuddin Syed,Mariko Yabe,Catherine C. Coombs,Nicole M. Caltabellotta,Michael Walsh,Kenneth Offit,Zsofia K. Stadler,Diana Mandelker,Jessica Schulman,Akshar Patel,John Philip,Elsa Bernard,Gunes Gundem,Juan E. Arango Ossa,Max Levine,Juan S. Medina Martinez,Noushin Farnoud,Dominik Glodzik,Sonya Li,Mark E. Robson,Choonsik Lee,Paul D.P. Pharoah,Konrad H. Stopsack,Barbara Spitzer,Simon Mantha,James A. Fagin,Laura Boucai,Christopher J. Gibson,Benjamin L. Ebert,Andrew L. Young,Todd E. Druley,Koichi Takahashi,Nancy K. Gillis,Markus Ball,Eric Padron,David M. Hyman,David M. Hyman,José Baselga,Larry Norton,Larry Norton,Stuart Gardos,Stuart Gardos,Virginia M. Klimek,Virginia M. Klimek,Howard I. Scher,Howard I. Scher,Dean F. Bajorin,Dean F. Bajorin,Eder Paraiso,Ryma Benayed,Maria E. Arcila,Marc Ladanyi,David B. Solit,Michael F. Berger,Martin S. Tallman,Montserrat Garcia-Closas,Nilanjan Chatterjee,Luis A. Diaz,Ross L. Levine,Lindsay M. Morton,Ahmet Zehir,Elli Papaemmanuil +69 more
TL;DR: It is found mutations are selected differentially based on exposures, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2).
Posted ContentDOI
Oncologic therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton,Ryan Ptashkin,Teng Gao,Lior Z. Braunstein,Sean M. Devlin,Daniel Kelly,Minal Patel,Antonin Berthon,Aijazuddin Syed,Mariko Yabe,Catherine C. Coombs,Nicole M. Caltabellotta,Michael Walsh,Kenneth Offit,Zsofia K. Stadler,Diana Mandelker,Jessica Schulman,Akshar Patel,John Philip,Elsa Bernard,Gunes Gundem,Juan E. Arango,Max Levine,Juan Medina,Noushin Farnoud,Dominik Glodzik,Sonya Li,M.E. Robson,Choonsik Lee,Paul D.P. Pharoah,Konrad H. Stopsack,Barbara Spitzer,Simon Mantha,James A. Fagin,Laura Boucai,Christopher J. Gibson,Benjamin L. Ebert,Andrew L. Young,Todd E. Druley,Koichi Takahasi,Nancy K. Gillis,Markus Ball,Markus Ball,Eric Padron,David M. Hyman,David M. Hyman,José Baselga,Larry Norton,Larry Norton,Stuart Gardos,Stuart Gardos,Virginia M. Klimek,Virginia M. Klimek,Howard I. Scher,Howard I. Scher,Dean F. Bajorin,Dean F. Bajorin,Eder Paraiso,Ryma Benayed,Maria E. Arcila,Marc Ladanyi,David B. Solit,Michael F. Berger,Martin S. Tallman,Montserrat Garcia-Closas,Nilanjan Chatterjee,Luis A. Diaz,Ross L. Levine,Lindsay M. Morton,Ahmet Zehir,Elli Papaemmanuil +70 more
TL;DR: It is shown that previously treated patients have increased rates of CH, with enrichment of mutations in DNA Damage Response genes (TP53, PPM1D, CHEK2), and exposure to radiation, platinum and topoisomerase II inhibitors have the strongest association with CH with evidence of dose-dependence and gene-treatment interactions.